NEW YORK (GenomeWeb) – GE Healthcare today announced a deal between its affiliate Clarient Diagnostic Services and GlaxoSmithKline to create a network of clinical laboratories to identify genetic mutations associated with different tumor types.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
